TrialDiabetes, obesity & metabolism2026

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis.

Jan Oscarsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.